Acrivon reports positive ACR-368 Phase 2b data in serous EC; ACR-2316 shows tumor shrinkage in Phase 1

Acrivon Therapeutics, Inc.

ACR-368 Phase 2b: 39% ORR overall; in serous EC ≤2 prior lines, cORR 52% (N=23) and 67% in BM+ (N=12). Arm 3 expanding to EU, enrollment complete Q4 2026.
ACR-2316 Phase 1: 33 patients dosed; tumor shrinkage in 9/20 evaluable; confirmed PR in EC, unconfirmed PRs in SCLC and sqNSCLC. Two weekly schedules set.
ACR-6840, a potential first-in-class CDK11 inhibitor, nominated as development candidate; IND submission planned for Q4 2026.
Preliminary cash, cash equivalents and investments ~$119M as of Dec 31, 2025, expected to fund operations into Q2 2027.
Phase 3 confirmatory protocol for ACR-368 + anti-PD-1 submitted to FDA Nov 2025; global trial readiness expected mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.